At Health 2.0 panel, VCs agree that digital health is in a bubble
VCs from Sanofi Ventures, Canaan Partners and GE Ventures said increasing investment along with declining exit activity indicates a bubble in the industry.
VCs from Sanofi Ventures, Canaan Partners and GE Ventures said increasing investment along with declining exit activity indicates a bubble in the industry.
Startup entrepreneurs opened up on a panel at the Health 2.0 conference in Santa Clara about the drivers and challenges of applying big data to healthcare.
A look at some of the most interesting startups from 2018's Health 2.0's LAUNCH! event.
At the Health 2.0 conference in Santa Clara a range of healthcare players from large employers to young startups spoke about their approaches to developing and implementing digital therapeutics.
The $50,000 challenge was sponsered by the Robert Wood Johnson Foundation to help find a tech-enabled approach to addressing substance abuse of opioids.
Panelists at the Health 2.0 Provider Symposium pointed to the necessity of building aligned incentives to promote data sharing and drive innovation.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
At the annual Health 2.0 conference in Silicon Valley, a panel of venture capitalists describe areas of health tech that do not appeal to them.
Clinical data alone cannot transform healthcare as data from devices, sensors, social media and other sources need to be leveraged to enable behavior change and improve outcomes, says the former national coordinator of the ONC.
Science 37 illustrated a way forward for pharma companies to improve clinical trial recruitment through social media and remote monitoring, reducing drug development costs.
New technologies are being scrutinized by hospital technology assessment committees and at Health 2.0, some entrepreneurs share frustrations and some advice on how to navigate the hurdle they represent.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
At Health 2.0, BTG Digital Health Innovation Director Amanda Goltz talked about how digital health could help make it a more powerful player in pharma.
CB Insights digital health stats for Q4 added up for the full year 2015 reveal $4.6 billion in digital health deals. It is part of a larger look at technology investments in 2015?.
One company sees digital health as a way to do virtual liver biopsies
A look at some of the digital health investment issues raised at recent conferences from Stanford Medicine X to Rock Health Summit to Health 2.0.
Talix zeroes in on the challenge of optimizing reimbursement codes for physicians, payers and accountable care organizations.